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In this issue, Babault et al. present a structural analysis of the PDZ domain of the PTPN4 phosphatase, free
and bound to target peptides. This allows them to enhance the cell-killing properties of a pro-apoptotic
peptide dramatically.PDZs are an abundant class of globular
domains with 267 occurrences in the
human proteome (te Velthuis et al., 2011).
Human proteins often contain several
copies of PDZs (up to 13) in their se-
quence. PDZs adopt a conserved beta
sandwich fold with five to six antiparallel
beta strands and two alpha helices,
and mainly recognize linear motifs that
are primarily situated at the extreme
C termini of their partner proteins (Doyle
et al., 1996). The last residue (referred to
as position p0) in PDZ-binding motifs is
usually Val or Leu. The third last peptide
residue (position p-2) can be either Thr or
Ser (class I), hydrophobic (class II), or Glu
or Asp (class III), thereby defining three
main categories of PDZ-binding motifs
(Songyang et al., 1997). PDZs mediate
protein-protein interactions within tran-
sient signal transduction complexes con-
trolling functions such as cell polarity, tight
junctions, and intercellular communication
(Nourry et al., 2003). Due to intensive
investigationby research teamsandstruc-
tural biology consortia, the structures of
about 120 humanPDZs have been solved,
and formost of the other humanPDZs, the
structure of one or several very closely
related orthologous PDZ domains is avail-
able in theProteinDataBank (PDB). Under
these circumstances, given the large
amount of available structural information,
one might question the significance of yet
another study devoted to the structure of
a human PDZdomain bound to C-terminal
target peptides.
The paper of Babault et al. (2011), pub-
lished in this issue of Structure, shows
that structural studies on PDZs can
still lead to novel and exciting findings.
The study focuses on PTPN4, a member
of a small family of cytosolic protein tyro-
sine phosphatases (PTPN3, PTPN4, and
PTPN13), which contain one (for PTPN31350 Structure 19, October 12, 2011 ª2011 Eand PTPN4) or five (for PTPN13) PDZ
domains that mediate the interactions of
these PTPs with their specific ligands or
substrates.
Previously, the same research group
had shown that the envelope glycoprotein
(G-att) of an attenuated rabies virus strain
selectively bound to the PDZ domain of
PTPN4 tyrosine phosphatase, and that
this interaction led to the stimulation of
apoptosis of the infected neuron cells,
thereby explaining the attenuated pheno-
type of that virus strain (Pre´haud et al.,
2010). Furthermore, it was shown that a
cell-penetrating peptide comprising at its
C terminus the 13 last C-terminal residues
of G-att retained part of the pro-apoptotic
effect of the full-length G-att protein.
In the present work, Babault et al.
(2011) built on the initial findings of Pre´-
haud et al. (2010) to: (1) finely analyze,
by a combination of X-ray and NMRmeth-
odologies, the structural determinants of
the interaction with the PTPN4 PDZ
domain of their initial pro-apoptotic
peptide as well as of a number of its vari-
ants; (2) demonstrate that the in vitro
binding strength of the various peptides
for the PDZ domain correlates with their
cell-killing effects; and (3) deduce, from
their structural analysis, the sequence of
a novel peptide, which turns out to bind
to the PDZ domain with a 40-fold higher
affinity (Kd = 1 uM) as compared to their
previously best binding peptide (Kd = 42
uM). Remarkably, this optimized binding
peptide also displays the strongest cel-
killing effects as compared to all the other
peptides previously tested.
This works is a nice example of how
structural biology can be used both for
investigating interesting biological ques-
tions and engineering new tools. Indeed,
the cell-killing peptide designed in the
study has a high potential for applica-lsevier Ltd All rights reservedtions in both an academic and a clinical
setting.
Of note, two structures of the PTPN4
PDZ were already available in PDB prior
to the work of Babault et al. (2011): an
apo NMR structure solved by the Riken
initiative and a peptide-bound crystal
structure solved by the Toronto Consor-
tium. Despite that, Babault et al. solved
their structures from scratch, and one
may wonder why they decided to do so
rather than use the available structures
to swiftly produce homology models of
the complexes they were interested in.
However, would they have taken the short
cut approach, they might not have spent
enough time on these complexes to
make the observations that led them to
the design of highly active peptides. One
interesting lesson of this work is that it
seems to illustrate the value of the ‘‘old-
fashioned, slow-throughput’’ structural
biology, which allows one to deeply learn
all details of a single structure during
the slow, careful process of structure
determination, versus ‘‘modern’’ high
throughput structural biology. The other
key to theseexciting findingswascertainly
the group’s unique expertise in the biology
of rabies protein G and its interference
with PTPN4 function.
Interestingly, proteins from other
viruses were shown to bind via their
C-terminal sequences to members of the
PTPN family and to interfere with their
cellular functions for promoting viral repli-
cation (Javier, 2008; Liu et al., 2010). For
instance, the oncoprotein E6 produced
by the human papillomaviruses (HPV) re-
sponsible for cervical cancer contains a
PDZ-binding motif that interacts with
several host PDZ domains. Deletion of
the PDZ-binding motif in HPV16 E6
impaired its capacity to promote cancer
in transgenic mice (Simonson et al.,
Structure
Previews2005), indicating that binding of E6 to PDZ
domains might be implicated in the devel-
opment of cervical cancer. Remarkably,
E6 was found to bind to PTPN3, a very
close paralog of PTPN4, via the PDZ
domain of PTPN3 (Jing et al., 2007).
Indeed, the last five residues at the
C terminus of HPV18 E6 read ‘‘RETQV,’’
which is a very close sequence to the
last five residues of the optimized PTPN4-
binding cell killing peptide of Babault et al.
(2011) (RETEV). It will be very interesting
to investigate whether the cell-pene-
trating PTPN4-binding peptides devel-
oped by Babault et al. interfere with the
interaction of HPV E6 with PTPN3 and/orpromote the induction of apoptosis of
HPV-positive cancer cell lines, such as
HeLa, SiHa, or CaSki.REFERENCES
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Our understanding of poly-ADP-ribosylation as a posttranslational modification was limited by the lack of
structural information on poly-ADP-ribose (PAR) hydrolysing enzymes. A recent study in Nature (Slade
et al., 2011) reports the structure of PAR glycohydrolase (PARG), revealing unexpected similarity to the
ubiquitous ADP-ribose-binding macrodomains.Poly-ADP-ribosylation is a reversible post-
translational modification (PTM) that oc-
curs mostly in response to cellular stress
(e.g., DNA strand breaks) and is catalyzed
by members of the PAR polymerase
(PARP) family. Utilizing NAD+ as a sub-
strate, PARP enzymes form complex
branched PAR polymers covalently at-
tached to target proteins, such as nuclear
histones. The best-characterized member
of the PARP family is PARP-1, which cata-
lyzes more than 90% of the PAR syn-
thesis that occurs rapidly in response to
different types DNA damage. Although still
lacking a complete understanding, the
mechanistic and functional aspects of
PARsynthesis havebeenextensively char-
acterized, and structural information for all
domains of PARP-1 is available (Langelier
et al., 2011). Much progress is also being
made with regard to how PAR functions incells and how this PTM is recognized by
various cellular machineries.
Although PARP-1 and PARylation have
been known for over forty years, it is the
discoveries in recent years of macrodo-
mains and PAR-binding zinc fingers
(PBZ) as readout modules for ADP-ribose
(Karras et al., 2005; Ahel et al., 2008) that
has ignited interest in the field and given
us badly needed new tools for this elusive
PTM. Crystal structures of several macro-
domain proteins bound to ADP-ribose
provide atomic insight into how these
globular protein modules appear de-
signed to recognize ADP-ribose moieties
deep within their extended nucleotide
binding pocket. Further, NMR structures
of PBZ domains have been highlighted
an alternativemechanism of PAR recogni-
tion (Karras et al., 2005; Timinszky et al.,
2009; Eustermann et al., 2010).In sharp contrast, we had no structural
insight into the mechanism of how
PAR chains can be rapidly removed
from the modified proteins. While it was
known that PARG enzymes catalyze the
breakdown of PAR into individual ADP-
ribose moieties and that the PARG null
mutation causes lethality in mouse
embryos (Koh et al., 2004), underscoring
the physiological importance of PAR
catabolism, no structures on PARG ex-
isted. There was also uncertainty in the
community as to whether PARG may be
able to cleave off terminal ADP-ribose
moieties (exo-), ‘‘internal’’ O-glycosidic
bonds (endo-activity), and/or also remove
the ADP-ribose moiety from mono-ADP-
ribosylated side chains (Koch-Nolte
et al., 2009).
In a recent Nature report, Slade et al.
(2011) were able to gain high-resolution2011 Elsevier Ltd All rights reserved 1351
